Board of Pharmacy Update

Welcome to a monthly news roundup from the California State Board of Pharmacy. More information about news reported here is on the Board’s website, [www.pharmacy.ca.gov](http://www.pharmacy.ca.gov).

Recent news:
- The Board has developed a **sample collaborative practice agreement** for pharmacists to provide medication-assisted treatment (MAT) to patients with opioid use disorder (OUD) in collaboration with a medical care provider.
- The CPJE was administered October 16 and 17 to more than 600 pharmacist candidates. Results are expected in early November.
- The **Licensing Committee** met via teleconference October 20. The agenda, materials and webcast recording are posted on the committee meetings page.
- The **Legislation and Regulation Committee** and the **Enforcement and Compounding Committee** met separately via teleconference October 27. Agendas, materials and webcast recordings can be found on the committees’ meetings pages.
- The Board met via teleconference October 27-28. The meeting agenda, materials, action items and webcast recording are posted on the [Board Meetings](http://example.com) page.
- An emergency rulemaking to add section 1747, Independent HIV Preexposure and Postexposure Prophylaxis Furnishing, to Title 16 of the California Code of Regulations (CCR) has been extended to February 26, 2021. The [Notice of Approval](http://example.com) and the **text of CCR section 1747** are posted on the [Approved Regulations](http://example.com) page.

Coming up:
- The Board’s office in Sacramento will be closed in observance of state holidays November 11 (Veterans Day) and November 26-27 (Thanksgiving).

A final word:
- The Board advises licensees that the Food and Drug Administration (FDA) has issued important guidance related to the federal Food, Drug and Cosmetic Act. The complete guidance document, [Wholesale Distributor Verification Requirement for Saleable Returned Drug Product and Dispenser Verification Requirements When Investigating a Suspect or Illegitimate Product — Compliance Policies](http://example.com), is available on the [FDA website](http://example.com).

###